Circulating Autoantibodies to Phosphorylated α-Enolase are a Hallmark of Pancreatic Cancer. by Tomaino, B et al.
 1 
 
 
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
 J Proteome Res. 2011 Jan 7;10(1):105-12. doi: 10.1021/pr100213b 
 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
http://pubs.acs.org/doi/abs/10.1021/pr100213b 
 
 2 
Circulating autoantibodies to phosphorylated α-
enolase are a hallmark of pancreatic cancer 
Barbara Tomaino1,2*, Paola Cappello1,2*, Michela Capello1,2, Claudia Fredolini1,2,11, Isabella 
Sperduti3, Paola Migliorini4, Paola Salacone5, Anna Novarino6, Alice Giacobino6, Libero 
Ciuffreda6, Massimo Alessio7, Paola Nisticò8, Aldo Scarpa9, Paolo Pederzoli10, Weidong Zhou11, 
Emanuel F. Petricoin, III11, Lance A. Liotta11, Mirella Giovarelli1,2, Michele Milella12, Francesco 
Novelli1,2 
 
1. Center for Experimental Research and Medical Studies (CeRMS), San Giovanni Battista 
Hospital, Turin, Italy 
2. Department of Medicine and Experimental Oncology, University of Turin, Turin, Italy  
3. Divisions of Biostatistics, Regina Elena National Cancer Institute, Rome, Italy 
4. Clinical Immunology Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy  
5. Gastroenterology Unit, Department of Internal Medicine, San Luigi Gonzaga Hospital, 
Orbassano, Turin, Italy 
6. Centro Oncologico Ematologico Subalpino (COES), San Giovanni Battista Hospital, Turin, Italy 
7. Proteome Biochemistry, San Raffaele Scientific Institute, Milan, Italy 
 3 
8. Divisions of Immunology, Regina Elena National Cancer Institute, Rome, Italy 
9. Department of Pathology, University of Verona, Verona, Italy 
10. Department of Surgical and Gastroenterological Sciences, University of Verona, Verona, Italy 
11. Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, 
Virginia, USA 
12. Divisions of Medical Oncology, Regina Elena National Cancer Institute, Rome, Italy 
 
 *These authors contributed equally to this work 
 
*Corresponding Author: Francesco Novelli, PhD 
Center for Experimental Research and Medical Studies (CeRMS) 
San Giovanni Battista Hospital 
Via Cherasco 15, 
10126 Turin, Italy.  
Tel: +39-011-633-4463  
Fax: +39-011-633-6887 
E-mail: franco.novelli@unito.it 
 4 
Abstract 
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis and no diagnostic markers have, 
as yet, been defined. In PDAC patients, α-enolase (ENOA) is up-regulated and elicits the 
production of autoantibodies. Here, we analyzed the autoantibody response to post-translational 
modifications of ENOA in PDAC patients. ENOA isolated from PDAC tissues and cell lines was 
characterized by two-dimensional electrophoresis (2-DE) western blot (WB), revealing the 
expression of six different isoforms (named ENOA1,2,3,4,5,6) whereas only 4 isoforms 
(ENOA3,4,5,6) were detectable in normal tissues. As assessed by 2-DE WB, 62% of PDAC 
patients produced autoantibodies to the two more acidic isoforms (ENOA1,2) as opposed to only 
4% of controls. Mass spectrometry showed that ENOA1,2 isoforms were phosphorylated on serine 
419. ROC analysis demonstrated that autoantibodies to ENOA1,2 usefully complement the 
diagnostic performance of serum CA19.9 levels, achieving approximately 95% diagnostic accuracy 
in both advanced and resectable PDAC. Moreover, the presence of autoantibodies against ENOA1,2 
correlated with a significantly better clinical outcome in advanced patients treated with standard 
chemotherapy. In conclusion, our results demonstrate that ENOA phosphorylation is associated 
with PDAC and induces specific autoantibody production in PDAC patients that may have 
diagnostic value. 
Keywords: antibodies/ mass spectrometry/ pancreatic ductal adenocarcinoma/ serological proteome 
analysis/ two-dimensional electrophoresis/ tumor associated antigen 
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Introduction 
 
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer death in both 
sexes in United States and Europe.1 Most patients die within 12 months and only 4% survive for 
five years after diagnosis. Surgical resection is the only potentially curative option. However, the 
absence of early symptoms or clinical-pathological markers results in diagnosis at a late, inoperable, 
stage in more than 80% of cases.1, 2 Biomarkers for the early detection of PDAC or even its 
differentiation from chronic pancreatitis (CP) are lacking. The only serological marker described, 
CA19.9, may also be elevated in non-malignant conditions, such as acute and chronic pancreatitis, 
as well as hepatitis and biliary obstruction,3 and has discriminating power only when high cut-off 
values are used.4 
We have observed that PDAC patients have circulating CD4+ T cells recognizing alpha-enolase 
(ENOA), a key glycolytic enzyme up-regulated in PDAC 5 and in other tumors.6-10 The presence of 
ENOA-specific CD4+ T cells suggests the existence of anti-ENOA-antibody-producing B cells. In 
addition, the over-expression of this enzyme may promote the overcoming of immune tolerance, 
and often results in autoantibody production.11 Notably, ENOA has been suggested as a potential 
biomarker of pancreatic cancer.12 By using a serological proteome analysis (SERPA) approach, we 
have identified, in serum of PDAC patients, autoantibodies directed against a number of metabolic 
enzymes that are often up-regulated in PDAC.13 In this paper we have evaluated: i) the expression 
and phosphorylation status of ENOA in PDAC cells; ii) the autoantibody response to 
phosphorylated ENOA in a large cohort of PDAC patients and their ability, alone or in combination 
with CA19.9, to discriminate PDAC patients from controls; iii) the correlation of anti-
phosphorylated ENOA autoantibody response and clinical-pathological variables of advanced 
PDAC patients treated with gemcitabine-based first-line chemotherapy. 
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Experimental Section 
 
Sera Specimens. The study was conducted with ethical approval from the Ethical Committees of 
the Dept. of Internal Medicine, University of Turin and Regina Elena National Cancer Institute, 
Rome. Serum samples were isolated from venous blood with the informed consent of patients and 
healthy donors and stored at −80°C until use. De-identified numeric specimen codes were used to 
protect the identity of the individuals. Diagnosis of PDAC or any other cancer was always 
confirmed by histological or cytological analysis. Sera from 120 PDAC patients, with clinical 
features described in Table 1, were tested and the resulting reactivities were compared with those of 
control sera from the following sources: 40 healthy subjects (HS, M/F: 14/26; median age, 71 years; 
range, 57−87 years) without a prior history of cancer or autoimmune disease; 50 non-PDAC cancer 
patients (9 liver, 12 breast, 9 colon, 19 lung and 1 ovarian; M/F: 24/26; median age, 69 years, range, 
44−86 years); 46 chronic pancreatitis patients (CP, M/F: 26/20; median age, 58 years; range, 22−74 
years); 12 autoimmune diseases patients (AD, 3 Mixed Cryoglobulinemia, 2 Meniere's Syndrome, 4 
Rheumatoid Arthritis, 2 Systemic Lupus Erythematosus, and 1 Autoimmune Pancreatitis; M/F: 3/9; 
median age, 49 years; range, 38−79 years). 
Two-dimensional electrophoresis and western blot analysis. Normal pancreatic (NP) tissues 
from six patients surgically treated for diseases not related to the pancreas, and PDAC tissues from 
twelve patients surgically treated (stage II of PDAC) were obtained frozen from Regina Elena 
National Cancer Institute (Rome, Italy) and used for 2-dimensional electrophoresis (2-DE) western 
blot (WB). Frozen tissue was homogenized in 2-DE lysis buffer, subjected to 2-DE and 
electroblotted onto a nitrocellulose membrane (GE Healthcare Bio-Sciences, Uppsala, Sweden) as 
previously described.13 Proteins from 107 CF-PAC-1, (ECACC ref. no. 91112501), MiaPaCa-2 
(ECACC ref. no. 85062806) and BxPC-3 (ECACC ref. no. 93120816) PDAC cell lines and from 
107 Saos-2 (ECACC ref. no. 89050205) human epithelial-like osteosarcoma cell line were 
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solubilized, subjected to 2-DE and electrotransferred onto a nitrocellulose membrane (GE 
Healthcare). ENOA isoforms were revealed with mouse anti-α-enolase monoclonal antibody (mAb) 
19/12 14 (for 1 h, 1:1000) and horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (1 h, 
1:2000, Santa Cruz Biotechnology, Santa Cruz, California, USA) as a secondary antibody. Sera 
from PDAC and controls were tested to determine IgG concentration by using a commercial kit 
(Human IgG ELISA Quantitation Set from Bethyl Laboratories, provided by Tema Ricerche, 
Bologna, Italy). Sera reactivity to ENOA was tested on PDAC cell lines by using each serum at 
working dilution of 0.1 mg/ml of IgG for 4 h, and incubated with HRP-conjugated rabbit anti-
human IgG (90 min, 1:1000, Santa Cruz Biotechnology) as a secondary antibody. Each serum was 
screened on three replica blots from the CF-PAC-1 cell line, and reactivity was confirmed by 
screening once on blots from the MiaPaCa-2 and the BxPC-3 cell lines. Immunodetection was 
accomplished by ECL PLUS (Enhanced Chemiluminescence, GE Healthcare Bio-Sciences). The 
resulting chemifluorescent signals were scanned with “ProXPRESS 2D” (PerkinElmer) with an 
excitation/emission filter setting of 460/80, 530/30 respectively and for an exposure time of 12 s. 
Images were recorded in TIFF format. The volume of ENOA1,2 spots recognized by autoantibodies 
was calculated after background subtraction using “ProFinder 2D” (PerkinElmer) software and 
reported as arbitrary units (AU). 
 
Nano-liquid chromatography tandem mass spectrometry analysis of ENOA 
phosphorylation. Six ENOA spots were excised from preparative Coomassie Brilliant Blue stained 
CF-PAC-1 2-DE gels and the in-gel digestion by trypsin was performed according to standard 
procedure.15 The extracted peptides were analyzed by reversed-phase liquid chromatography 
nanospray tandem mass spectrometry (LC-MS/MS) using an LTQ-Orbitrap mass spectrometer 
(ThermoFisher).16 The reversed-phase LC column was slurry-packed in-house with 5 μm, 200 Å 
pore size C
18 
resin (Michrom BioResources, CA) in a 100 μm i.d. × 10 cm long piece of fused silica 
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capillary (Polymicro Technologies, Phoenix, AZ) with a laser-pulled tip. After sample injection, the 
column was washed for 5 min with mobile phase A (0.1% formic acid), and peptides were eluted 
using a linear gradient of 0% mobile phase B (0.1% formic acid, 80% acetonitrile) to 45% mobile 
phase B in 120 min at 200 nL/min, then to 100% B in an additional 5 min. The LTQ-Orbitrap mass 
spectrometer was operated in a data-dependent mode in which each full MS scan (60,000 resolving 
power) was followed by eight MS/MS scans where the eight most abundant molecular ions were 
dynamically selected and fragmented by collision-induced dissociation (CID) using a normalized 
collision energy of 35%. Tandem mass spectra collected by Xcalibur (version 2.0.2, 
ThermoElectron, San Jose, CA, USA) were searched against the NCBI human protein database 
(released on September 5, 2009, 34180 sequences) using Bioworks 3.3.1 (ThermoFisher, 
Extract_msn for peak picking software and SEQUEST for search engine) with full tryptic cleavage 
constraints, static cysteine alkylation by iodoacetamide, and variable phosphorylation of 
Ser/Thr/Tyr and methionine oxidation. Mass tolerance for precursor ions was 10 ppm and mass 
tolerance for fragment ions was 0.5 Da. Confident phosphopeptide identifications were determined 
using stringent filter criteria “ranked top #1; Xcorr versus charge 1.8, 2.5 for 2+, 3+ ions; mass 
accuracy 3 ppm; probability of randomized identification of peptide < 0.05” for database match 
scoring followed by manual evaluation of the results. The estimated "false discovery rate (FDR)" is 
lower than 1% by searching a combined forward-reversed database. 
“On-blot” phosphatase treatment. CF-PAC-1 2-DE gels were electroblotted onto nitrocellulose 
membranes and, after 2 h blocking with 5% nonfat dry milk in PBS, were either incubated or not 
for 15 h at 30°C on a rocker in PBS containing 600 U/ml of lambda protein phosphatase (λPPase, 
Sigma Chemical Co, St. Louis, Missouri, USA), 40 μl/ml of 20 mM MnCl2 and 40 μl/ml of λPPase 
buffer. The reactivity of a pool of three ENOA1,2+ sera (diluted in PBS to reach the final 
concentration of 0.1 mg/ml of IgG) was subsequently assessed. 
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Western blot with pre-adsorbed sera. A pool of three ENOA1,2+ sera was diluted in PBS to 
reach the final IgG concentration of 0.1 mg/ml and incubated for 15 h at 4°C on a rocker with 20 
μg/ml of recombinant α-enolase (rENOA; supplementary data). The reactivity of these pre-
adsorbed sera was evaluated by CF-PAC-1 2-DE WB as described. 
Statistical analysis. All statistics were computed using the SPSS (17.0) and MedCalc softwares. 
Data ranges and 95% confidence intervals (95% CI) were reported for descriptive statistics. A 2-
sided P value of <0.05 was considered to be statistically significant. Association between clinical-
pathological variables and the presence of anti-ENOA1,2 autoantibodies was tested by the 
Pearson’s χ2 test, Mantel-Haen-Haenszel test or Fisher’s exact test, as appropriate. Progression-free 
survival (PFS) was calculated by the Kaplan-Meier product-limit method from the first day of 
treatment to the date of progression or death for any cause. If a patient was not dead, survival was 
censored at the time of the last visit. The log-rank test was used to assess differences between 
subgroups. The Hazard Ratio (HR) and the confidence limits at 95% were estimated for each 
variable using the Cox univariate model and adopting the most suitable prognostic category as the 
reference group. A multivariate Cox proportional Hazard model was also developed using stepwise 
regression (forward selection) with predictive variables that were significant at univariate analysis. 
The cut-off P-values to enter in or to be removed from the multivariate model were set at 0.10 and 
0.15, respectively. Multivariate logistic regression was performed to assess the diagnostic value of 
CA19.9 serum levels and the absence or presence of anti-ENOA1,2 autoantibodies, alone or 
combined, in a cohort of 98 PDAC patients and 63 controls (HS+CP) for whom both data were 
available. A logistic equation including the coefficients of the regression analysis was then 
constructed to calculate an estimation of individual patient’s probability of having PDAC: 
probability of PDAC = (Exp∑(X x B) + intercept(α))/1+(Exp∑(X x B) + intercept(α)), where X x B is the coefficient B 
for each single confounding factor X. We then generated receiver operating characteristic (ROC) 
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curves and compared their area under the curves (AUC, c-statistics) to measure the diagnostic 
accuracy of the model.17, 18 
 
Results 
 
Two acidic ENOA isoforms are expressed in PDAC. In agreement with previous studies,6-9 data 
obtained using mRNA microarrays, immunohistochemistry and WB indicate that ENOA is up-
regulated in PDAC.5 To characterize the expression of ENOA in PDAC, we used a 2-DE WB-based 
approach. In normal pancreatic tissues (NP, n=6), 2-DE WB using an anti-ENOA mAb identified 
four ENOA isoforms (named ENOA3,4,5,6). These isoforms had a similar 47 kDa molecular 
weight and pI ranging from 6.6 to 8 (Figure 1A). In surgical PDAC specimens (n=12), as well as in 
PDAC cell lines (CF-PAC-1, MiaPaca-2 and BxPC3), ENOA3,4,5,6 expression was increased 
approximately 2-fold, as compared to NP, and two more acidic isoforms (pI 6, named ENOA1,2), 
barely detectable in NP, became clearly apparent (fold increase > 3, Figure 1A). Conversely, 
ENOA1,2 isoforms were not detected in the Saos-2 osteosarcoma cell line (Figure 1B). In PDAC 
cell lines, MALDI-MS/MS analysis confirmed that all 2-DE WB-detected isoforms were indeed 
ENOA isoforms (Supplementary Table 1). 
Sera from PDAC patients contain autoantibodies to ENOA1,2 isoforms. Using CF-PAC-1 
cell lysates as the source of ENOA, the presence of circulating autoantibodies to PDAC-associated 
ENOA1,2 isoforms was analyzed by 2-DE WB in 120 sera from PDAC patients (clinical features 
described in Table 1) and reactivity was compared to that of sera from 40 HS, 46 CP, 12 AD, and 
50 non-PDAC patients (Table 2 and Figure 2). Sixty-two percent of PDAC patients produced 
autoantibodies directed against ENOA1,2 (hereafter referred to as ENOA1,2+); conversely, such 
reactivity was observed in only 4% of non-PDAC and 9% of CP patient sera (Table 2). A similar 
pattern of serum reactivity was observed using MiaPaCa-2 or BxPC-3 cell lines as the source of 
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ENOA (data not shown). Of note, sera from ENOA1,2+ patients were able to recognize ENOA1,2 
not only in cell line lysates but also in lysates from PDAC biopsies (data not shown). 
Sera from PDAC patients contain autoantibodies to phosphorylated ENOA1,2 isoforms. The 
2-DE pattern of ENOA1,2 isoforms suggested that they are phosphorylated. Next, we investigated 
whether autoantibodies to ENOA1,2 are directed to phosphorylated epitopes. To this purpose 
nitrocellulose membranes blotted from CF-PAC-1 2-DE gels were treated with λPPase, that 
removes phosphate groups from proteins, and the ability of ENOA1,2+ sera to react with blotted 
ENOA was tested. This “on-blot” λPPase treatment abolished the reactivity of ENOA1,2+ sera 
(Figure 3), while the reactivity of anti-α-enolase mAb (which does not distinguish between 
phosphorylated and un-phosphorylated isoforms) was not affected (Figure 3, lower panels). This 
indicates that removal of phosphate groups selectively affects the reactivity of ENOA1,2+ patient 
sera, suggesting that they contain autoantibodies against phosphorylated ENOA1,2 isoforms. 
Conversely, pre-incubation of ENOA1,2+ sera with un-phosphorylated recombinant ENOA 
(rENOA) did not alter their WB reactivity with ENOA1,2 (Figure 3). These data indicate that in 
PDAC sera autoantibodies to ENOA1,2 isoforms are indeed directed to phosphorylated ENOA. 
To further confirm the ENOA autoantibody reactivity observed in PDAC patients, 
phosphorylation of all six ENOA isoforms from CF-PAC-1 2-DE gels was analyzed by MS. Nano-
LC-MS/MS analysis revealed the presence of phosphorylation on a serine residue at position 419 
(413IEEELGpSKAK422) only in ENOA1,2 isoforms (accession number 4503571) (Figure 4), 
indicating that in PDAC ENOA is phosphorylated at serine 419. These data strongly suggest that 
autoantibodies that recognize ENOA1,2 are predominantly directed to serine 419-phosphorylated 
ENOA. 
The presence of autoantibodies to ENOA1,2 improves the diagnostic performance of 
CA19.9 in PDAC. Autoantibodies against ENOA1,2 discriminated PDAC patients from controls 
(HS, non-PDAC, CP and AD) with 62% sensitivity (95% CI: 52.9-70.4%) and 97% specificity 
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(95% CI: 93.7-99.5%). In addition, anti-ENOA1,2 autoantibodies were significantly more frequent 
in patients with normal CA19.9 serum levels (< 37 IU/ml), as compared to patients with 
pathological elevation of CA19.9 (91% vs 59%, respectively, p=0.04, data not shown). This 
observation prompted us to test the diagnostic performance of combined CA19.9 serum levels (≥ 37 
IU/mL) and anti-ENOA1,2 autoantibodies in a training set of 61 advanced PDAC patients at stage 
III and IV and 63 controls (HS+CP), using ROC analysis. As shown in Figure 5, combined 
CA19.9/ENOA1,2 discriminated PDAC patients from controls with 95.1% sensitivity and 94% 
specificity, with an overall diagnostic accuracy of 94±0.02% (p=0.0001). These results were further 
confirmed in a validation set of 37 resectable PDAC patients. This cohort includes stage II and III 
patients who underwent surgery with curative intent. In this setting, the combination of elevated 
CA19.9 serum levels and anti-ENOA1,2 autoantibodies resulted in an overall diagnostic accuracy 
of 95±0.03% (p=0.0001, Figure 5). Thus, in both settings, detection of anti-ENOA1,2 
autoantibodies usefully complemented the diagnostic performance of serum CA19.9 levels. 
The antibody response to ENOA1,2 correlates with clinical outcome in advanced PDAC 
patients. No significant associations were found between baseline PDAC patients’ clinical-
pathological characteristics (age, gender, previous surgery, histology, disease stage, Eastern 
Cooperative Oncology Group performance status-ECOG PS) and the presence or absence of 
autoantibodies to ENOA1,2. Interestingly, in a cohort of 77 advanced PDAC patients, at stage III 
and IV, who were evaluable for clinical outcome upon I-line gemcitabine-based chemotherapy, the 
presence of autoantibodies to ENOA1,2 and disease stage were the only independent predictors of 
disease control (complete or partial response and stable disease; p=0.017 and p=0.033, respectively) 
and longer progression-free survival (PFS) (p=0.002 for both variables, Table 3) at multivariate 
analysis. Moreover, when the analysis was restricted to patients who were able to mount a humoral 
immune response against any of the ENOA isoforms (n=51), ENOA1,2+ patients had a highly 
significant reduction in the risk of progression or death as compared to patients with autoantibodies 
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directed only against ENOA3,4,5,6 isoforms (p=0.0001 and p=0.004 for PFS and overall survival 
(OS), respectively), further supporting the clinical relevance of an autoantibody response to 
ENOA1,2 (Figure 6). 
 
Discussion 
 
The dismal prognosis and late presentation of PDAC in most patients emphasizes the need to 
improve the early detection of PDAC. To this purpose, starting from the observation that the 
expression of ENOA is up-regulated in PDAC (at mRNA and protein levels; 
http://www.genecards.org/index.shtml) 5-8, 19 compared with normal pancreatic tissues, we 
characterized ENOA expression in PDAC and the relative autoantibody response in PDAC patients’ 
sera. As a result of these studies, we demonstrate that two out of six ENOA isoforms (ENOA1,2) 
detectable by 2-DE WB are preferentially expressed in PDAC and that such isoforms are 
phosphorylated on serine 419. Although it is known that ENOA is phosphorylated in Ser/Thr/Tyr 
residues,20-24 this is the first evidence that in PDAC cells ENOA is phosphorylated in serine 419. 
The fact that the same phosphorylated peptide containing serine 419 was found in both ENO1,2 
isoforms suggests that additional differential post-transcriptional modifications (e.g. acetylation, 
methylation) are responsible for their different isoelectric point. Most importantly, here we provide 
evidence that ENOA1,2 isoforms induce an in vivo humoral response in a substantial proportion of 
PDAC patients (62%). Such reactivity is presumably directed against the phosphorylated serine 419 
residue and is specifically associated to PDAC, in that it is only sporadically observed in patients 
with inflammatory pancreatic diseases (CP), autoimmunity, and patients with non-PDAC 
malignancies. This would imply that the aberrant ENOA phosphorylation observed in PDAC may 
induce the overcoming of immune tolerance against this enzyme and trigger the antibody 
response.25 Autoantibodies to ENOA3,4,5,6 isoforms have indeed been found in the serum of 
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patients with lung carcinoma,26-28 acute leukemia,29 and multiple sclerosis,30 as well as in a small 
proportion of HS (this paper). Conversely, we found that autoantibody production against ENOA1,2 
was almost exclusively observed in PDAC patient sera. 
Of clinical relevance, ENOA1,2 autoantibodies are significantly more frequent in patients with 
normal CA19.9 levels, potentially complementing the performance of the most widespread 
serological test currently employed in the diagnostic workup of both cystic and solid pancreatic 
masses. CA19.9 immunoassay achieves high sensitivity and specificity only in the presence of a 
considerable tumor burden and when high cut-offs are used.4 Moreover, it may be elevated in non-
malignant conditions, such as acute and chronic pancreatitis, as well as hepatitis and biliary 
obstruction,3 and in other gastrointestinal and non-gastrointestinal cancers. Here we demonstrate 
that the combination of CA19.9 and anti-ENOA autoantibodies yields a diagnostic accuracy of 
approximately 95% not only in advanced PDAC patients undergoing palliative treatment, but also 
in patients who may be amenable to surgery with curative intent. In resectable PDAC, where the 
rate of abnormal CA19.9 serum level falls considerably,31 the simultaneous detection of 
autoantibodies to phosphorylated ENOA1,2 could thus provide a more finely-tuned diagnostic tool 
and warrants further confirmation in larger surgical series as well as a potential screening method 
for high risk populations.32 By 2-DE approach we provide the proof-of-concept that phosphorylated 
ENOA at serine 419 is specifically recognized by autoantibodies in PDAC patients. Development 
of a handy assay based on the capture of autoantibodies to phosphorylated serine 419 residue will 
allow to validate the diagnostic potential in a large cohort of patients. 
Finally, ENOA1,2+ patients exhibit a more favorable clinical course with a significantly lower 
proportion of disease progression and a consequently longer PFS upon gemcitabine treatment. 
Interestingly, this advantage seems to be restricted to patients who are able to mount a humoral 
immune response specifically directed against the phosphorylated isoforms ENOA1,2. This is 
clinically relevant in a disease, such as advanced PDAC, where only performance status and disease 
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stage have proved to reliably predict clinical outcome.33 The mechanism involved in the production 
of autoantibodies to ENOA in PDAC patients is presently unclear. The combined effect of 
increased anaerobic metabolism and gemcitabine treatment enhances ENOA expression and induces 
resistance to apoptosis.34 This, in turn, may stimulate the overcoming of immune tolerance to 
ENOA and trigger specific antibody production. Most interestingly, from a clinical perspective, 
ENOA is also expressed on the surface of many cell types including PDAC where it acts as a 
plasminogen receptor.5, 14, 35 It is therefore a suitable target for anti-ENOA1,2 IgG antibodies, which 
might, in turn, efficiently trigger antibody or complement-dependent cytotoxicity. In addition, as 
cancer progression is often associated with the ability to escape immune responses,36 the association 
of autoantibody production with a favorable clinical course may reflect a more efficient immune 
response in ENOA1,2+ PDAC patients. This hypothesis is supported by the observation that the 
peripheral blood of ENOA1,2+ PDAC patients contains ENOA-specific CD4+ and CD8+ T cells.5 In 
this context, the presence of autoantibodies to ENOA1,2 in PDAC patients might directly reflect the 
activation of anti-ENOA CD4+ T helper cells. 
In conclusion, this study indicates that serine 419-phosphorylated ENOA1,2 isoforms and the 
autoantibody response against them are specifically associated with PDAC and appear to influence 
its clinical course. Further investigations are needed to validate PDAC sera reactivity against 
phosphorylated ENOA1,2 in a large-scale study, as well as to fully evaluate their clinical 
usefulness. 
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Figure Legends 
Figure 1. Expression analysis of ENOA isoforms. (A) The protein extracts from PDAC (n=12) 
and normal tissues (NP, n=6) were separated by 2-DE, electroblotted onto nitrocellulose 
membranes and probed with anti-α-enolase mAb and with anti-actin polyclonal antibody as a 
loading control. 2-DE WB indicates the presence of six ENOA isoforms on cropped images from 2-
DE gels. The arrows indicate the ENOA1,2 isoforms position. Quantisation of ENOA isoform 
intensities on 2-DE WB are measured as arbitrary units (AU) and normalised on the total actin 
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intensity. The fold between PDAC and NP are indicated at the bottom. (B) 2-DE WB of the ENOA 
isoform expression in CF-PAC-1, MiaPaCa-2, BxPC-3 and Saos-2 cell lines. 
 
Figure 2. Sera reactivity against ENOA1,2. Colloidal Blue Coomassie stained image of 2-DE as 
compared with representative reactivity of sera from PDAC and HS by 2-DE WB on CF-PAC-1 
cell line. Numbered arrows indicate the ENOA1,2 isoforms. To establish the serum positivity to 
ENOA1,2 isoforms the volume of corresponding spots were calculated in each 2-DE WB. When the 
spot volume with the same pI and MW of that recognized by the anti-ENOA mAb was equal to the 
background, the sample was considered ENOA1,2 negative. For the ENOA1,2 positive sera (n= 74) 
the range of volume of ENOA1 recognized by autoantibodies varied from 0.4 x 106 to 38 x 106 
arbitrary units (AU) whereas that of ENOA2 varied from 1 x 106 to 30 x 106 AU. 
 
Figure 3. Analysis of sera reactivity to phosphorylated ENOA1,2. ENOA isoforms from CF-
PAC-1 cell line were separated by 2-DE and transferred onto nitrocellulose membrane. 
Representative reactivity of a pool of three ENOA1,2+ PDAC sera assessed alone on untreated 
membrane, alone on membrane treated “on blot” with λPPase or mixed with rENOA on untreated 
membrane is shown in upper panels. The reactivity of anti-α-enolase mAb is present at the bottom 
of each panel. Graph shows the quantisation analysis of ENOA isoforms probed by ENOA1,2+ sera. 
The relative intensities were normalised on the total ENOA intensity and expressed as arbitrary 
units (AU). The results are presented as means of three experiments ± SD. 
 
Figure 4. CID spectrum of the doubly-charged phosphopeptide 413IEEELGpSKAK422 from 
ENOA1,2 (accession number 4503571). The spectrum (upper panel) was labeled to show singly-
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charged b and y ions, as well as ions corresponding to neutral losses of the phosphate group and 
water. The lower panel is the table of the fragment assignments of this phosphopeptides, in which 
the matched b ions are colored with red, the matched y ions are colored with blue, the matched a 
ions are colored with green, the matched z ions are colored with purple, the matched b ions with 
neutral loss of NH3 or H2O are colored with yellow, and the matched y ions with neutral loss of NH3 
or H2O are colored with magenta. 
 
Figure 5. ROC analysis of sensitivity and specificity of combined CA19.9 (≥ 37 IU/mL) and/or 
ENOA1,2 positivity. Curves reflect individual patient’s probability of having PDAC calculated by 
a multivariate logistic regression model taking into account both CA19.9 serum levels and 
autoantibodies to ENOA1,2 in a set of advanced (n=61) and resectable (n=37) PDAC patients 
relative to HS+CP controls (n=63). 
 
Figure 6. Survival analysis in advanced PDAC patients undergoing chemotherapy according 
to anti-ENOA reactivity. Kaplan-Meier curves for progression-free survival (PFS) and overall 
survival (OS) relative to ENOA1,2+ (thick line) and ENOA3,4,5,6-only positive (dotted line) PDAC 
patients undergoing first-line palliative chemotherapy. Log-rank p=0.0001 and 0.004 for PFS and 
OS, respectively. 
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Table 1. Clinical features of 120 PDAC patients 
Characteristics   N %a 
Gender     
 Male  67 56 
 Female  53 44 
Age (years)     
 Mean 67 - - 
 Range 32-86 - - 
Stageb     
 IIA  4 3 
 IIB  21 17 
 III  27 22 
 IV  68 57 
Grading     
 Not reported  64 53 
 1  3 2 
 2  32 27 
 3  21 17 
Primary Site     
 Not reported  21 17 
 Head  60 50 
 Isthmus  8 7 
 Body  12 10 
 Tail  9 7 
 Body-Tail  10 8 
Metastatic sitesc     
 Abdominal Wall  1 - 
 Bone  3 - 
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 Liver  57 - 
 Lung  8 - 
 Lymph Nodes  15 - 
 Peritoneum  9 - 
ECOG PS     
 Not reported  38 32 
 0  34 28 
 1  42 35 
 ≥2  6 5 
Surgery with Radical Intent     
 Yes  38d 32 
 No  82 68 
Surgical Margin Status     
 R0  29 76e 
 R1  9 24 
Baseline CA19.9 (IU/ml)     
 Evaluable  98 82 
 Mean 3069 - - 
 Median 511 - - 
 Range 2-26818 - - 
First-Line Chemotherapyf   79 - 
 Evaluable  77 97g 
 Gem  60 76 
 Gem/Oxal  11 14 
 Gem/5-FU  4 5 
 Non-Gem  4 5 
ECOG PS, eastern cooperative oncology group performance status; 5-FU, 5-fluorouracil; Gem, 
gemcitabine; Oxal, oxaliplatin. 
aPercentages may not add up to 100 due to rounding. 
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bClassified according to the TMN classification of malignant tumor of the pancreas (UICC).37 
cTwenty-two patients had multiple metastatic sites. 
dSerum collection for anti-ENOA autoantibodies: analysis was performed at the time of surgery in 
14 patients and at the time of relapse in 24 patients. 
ePercentages are calculated on the total of thirty-eight patients undergoing surgery with radical 
intent. 
fFirst-line chemotherapy refers to palliative chemotherapy administered for relapsed, locally 
advanced inoperable, or metastatic disease. 
gPercentages are calculated on the total of 79 patients undergoing I-line chemotherapy. 
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Table 2. Frequencies of sera reactivity against ENOA1,2 
Serum Number of subjects ENOA1,2 positive sera (%) p Value* 
PDAC 120 74 (62%) - 
HS 40 0 (0%) P=0.0001 
Non-PDAC 50 2 (4%) P=0.0001 
CP 46 4 (9%) P=0.0001 
AD 12 0 (0%) P=0.0181 
*Two-tailed p values are referred to PDAC and are determined by Mantel-Haenszel χ2 test. 
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 Table 3. Cox regression analysis of outcome-predicting factors 
Multivariate 
 
HR (95% CI) p Value 
  DCR (logistic regression) 
Age (years) <67 vs >67 2.55 (0.92-7.03) 0.071 
Disease stage II-III vs IV 3.86 (1.12-13.3) 0.033 
Anti-ENOA1,2 Pos vs Neg 3.59 (1.26-10.2) 0.017 
  PFS (Cox regression) 
Age (years) >67 vs <67 1.61 (0.99-2.62) 0.051 
Disease stage IV vs II-III 2.77 (1.46-5.25) 0.002 
Anti-ENOA1,2 Neg vs Pos 2.20 (1.34-3.62) 0.002 
  OS (Cox regression) 
Disease stage IV vs II-III 3.15 (1.61-6.14) 0.001 
Surgery No vs Yes 3.14 (1.58-6.24) 0.001 
ECOG PS 1/2/3 vs 0 2.11 (1.22-3.63) 0.007 
Anti-ENOA1,2 Neg vs Pos 1.56 (0.93-2.64) 0.095 
  CI, confidence interval; DCR, disease control rate; ECOG PS, eastern cooperative oncology 
  group performance status; HR, hazards ratio.  
